Free Trial

Nevro (NVRO) Stock Price, News & Analysis

Nevro logo
$3.77 -0.02 (-0.53%)
(As of 05:26 PM ET)

About Nevro Stock (NYSE:NVRO)

Key Stats

Today's Range
$3.62
$3.83
50-Day Range
$3.59
$5.78
52-Week Range
$3.52
$22.52
Volume
344,080 shs
Average Volume
560,639 shs
Market Capitalization
$141.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.30
Consensus Rating
Reduce

Company Overview

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Nevro Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

NVRO MarketRank™: 

Nevro scored higher than 43% of companies evaluated by MarketBeat, and ranked 639th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nevro has received a consensus rating of Reduce. The company's average rating score is 1.77, and is based on no buy ratings, 10 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Nevro has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nevro's stock forecast and price target.
  • Earnings Growth

    Earnings for Nevro are expected to decrease in the coming year, from ($2.43) to ($2.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nevro is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nevro is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nevro has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.47% of the outstanding shares of Nevro have been sold short.
  • Short Interest Ratio / Days to Cover

    Nevro has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Nevro has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nevro does not currently pay a dividend.

  • Dividend Growth

    Nevro does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.47% of the outstanding shares of Nevro have been sold short.
  • Short Interest Ratio / Days to Cover

    Nevro has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Nevro has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nevro has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Nevro this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nevro insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Nevro is held by insiders.

  • Percentage Held by Institutions

    95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nevro's insider trading history.
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

Analysts Set Nevro Corp. (NYSE:NVRO) PT at $8.05
RBC Capital Remains a Hold on Nevro Corp (NVRO)
No one’s talking about these Trump trades
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Wells Fargo & Company Cuts Nevro (NYSE:NVRO) Price Target to $4.00
Citigroup Lowers Nevro (NYSE:NVRO) Price Target to $5.00
Nevro Corp (NVRO) Receives a Hold from Wells Fargo
Nevro price target lowered to $5 from $6 at Citi
See More Headlines

NVRO Stock Analysis - Frequently Asked Questions

Nevro's stock was trading at $21.52 at the start of the year. Since then, NVRO shares have decreased by 82.5% and is now trading at $3.77.
View the best growth stocks for 2024 here
.

Nevro Corp. (NYSE:NVRO) posted its earnings results on Monday, November, 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.40. The firm's revenue was down 7.0% on a year-over-year basis.

Top institutional investors of Nevro include ArrowMark Colorado Holdings LLC (11.72%), Engaged Capital LLC (6.55%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.68%) and Western Standard LLC (2.61%). Insiders that own company stock include Kashif Rashid, Shawn Mccormick and D Keith Grossman.
View institutional ownership trends
.

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

Last Earnings
11/11/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Fax
N/A
Employees
1,215
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.30
High Stock Price Target
$16.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+66.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.77
Research Coverage
13 Analysts

Profitability

Net Income
$-92,210,000.00
Pretax Margin
-17.89%

Debt

Sales & Book Value

Annual Sales
$419.15 million
Book Value
$8.10 per share

Miscellaneous

Free Float
36,273,000
Market Cap
$142.02 million
Optionable
Optionable
Beta
0.84

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NYSE:NVRO) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners